Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
31.44
-0.57 (-1.78%)
Dec 3, 2024, 12:21 PM EST - Market open
Akero Therapeutics Employees
As of December 31, 2023, Akero Therapeutics had 56 total employees, including 55 full-time and 1 part-time employees. The number of employees increased by 17 or 43.59% compared to the previous year.
Employees
56
Change (1Y)
17
Growth (1Y)
43.59%
Revenue / Employee
n/a
Profits / Employee
-$4,236,107
Market Cap
2.19B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Ardent Health Partners | 23,000 |
CONMED | 4,000 |
Premier | 2,900 |
NeoGenomics | 2,100 |
Amphastar Pharmaceuticals | 1,761 |
Beam Therapeutics | 436 |
Mirum Pharmaceuticals | 264 |
AKRO News
- 18 days ago - Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 19 days ago - Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 25 days ago - Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 2 months ago - INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - GlobeNewsWire
- 2 months ago - Akero Therapeutics: Good Candidate For The MASH Basket - Seeking Alpha
- 3 months ago - Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH - GlobeNewsWire